Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
1999-2-9
|
pubmed:abstractText |
9-Aminocamptothecin (9-AC) inhibited cell growth and DNA synthesis in HCT 116 human colon cancer cells in a concentration- and time-dependent manner. Interference with nascent DNA chain elongation was monitored using pH step alkaline elution. After a 3-day 9-AC exposure, 38% (10 nM) and 53% (50 nM) of the total [3H]DNA eluted with pH steps 11.3-11.7, compared to 9% in control cells. Effects on nascent DNA integrity were also evaluated by fixed elution with pH 12.1 buffer. After a 3-day exposure to 9-AC, 27% (10 nM) and 82.5% (50 nM) of the total [3H]DNA eluted relative to control. Paired bone marrow samples were then obtained in 10 patients before treatment and between 42 and 72 h of a continuous i. v. infusion of 9-AC (35-74 microgram/m2/h for 72 h). The mononuclear cells were incubated with [3H]dThd for 2 or 4 h, and then analyzed using either pH step or fixed pH alkaline elution, respectively. In seven patients receiving >/=47 microgram/m2/h 9-AC, 4% +/- 1.5% (mean +/- SE) of the total [3H]DNA eluted with pH steps </= 11.7 in the pretreatment samples compared to 13% +/- 3.6% during 9-AC (P = 0. 037). An altered fixed pH elution profile of nascent DNA was noted in two patients treated with 59 and 74 microgram/m2/h 9-AC compared to baseline. DNA synthesis was inhibited by 89% +/- 5% during infusion of >/=59 microgram/m2/h 9-AC (n = 7). Since hematological toxicity is dose limiting on this 9-AC schedule, these cellular pharmacodynamic studies provide evidence of a DNA-directed cytotoxic effect of 9-AC in a sensitive host target tissue.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Nov
|
pubmed:issn |
1078-0432
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
1
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1345-51
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9815930-Adult,
pubmed-meshheading:9815930-Aged,
pubmed-meshheading:9815930-Antineoplastic Agents,
pubmed-meshheading:9815930-Bone Marrow,
pubmed-meshheading:9815930-Camptothecin,
pubmed-meshheading:9815930-DNA,
pubmed-meshheading:9815930-Half-Life,
pubmed-meshheading:9815930-Humans,
pubmed-meshheading:9815930-Hydrogen-Ion Concentration,
pubmed-meshheading:9815930-Middle Aged
|
pubmed:year |
1995
|
pubmed:articleTitle |
Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples.
|
pubmed:affiliation |
National Cancer Institute-Navy Medical Oncology Branch, Clinical Oncology Program, Division of Cancer Treatment, National Cancer Institute, National Naval Medical Center, Bethesda, Maryland 20889-5105, USA.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|